Kilambi News
Wednesday, November 18, 2026

Pfizer licenses Starna in vivo CAR-T programs in $2.6 billion deal

Life Sciences Wednesday, November 18, 2026 - Updated Nov 18, 2026 11:47

Pfizer will pay Starna Therapeutics $330 million up front, with up to $2.3 billion more in milestones, for exclusive rights outside Greater China to three pre-IND in vivo CAR-T programs for autoimmune diseases.

Why it matters: The deal puts Pfizer into the in vivo CAR-T race, where cell therapies are reprogrammed inside the body rather than harvested and modified outside it, a preclinical approach Big Pharma rivals have been buying into for autoimmune disease.

Data as of Pfizer press release of November 18, 2026, read in full; all deal terms are Pfizer's own. Context on the in vivo CAR-T field from BioPharma Dive reporting of November 18, 2026, read in full. Developing item.

Pfizer said on Wednesday it has entered an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines, obtaining exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs focused on autoimmune diseases. Starna will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products.

Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology and in oncology, options to license compounds from a separate research collaboration, and an option to expand its territory to include Greater China. Pfizer will lead clinical development outside Greater China, plans to manufacture the finished drug product for the initial clinical trials at its facilities in the United States, and will have sole control over commercialization outside Greater China for all products.

Sources

  1. Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases - Pfizer Inc. - 2026-11-18
  2. Pfizer leaps into 'in vivo' CAR-T with latest China deal - BioPharma Dive - 2026-11-18